Accessing Diverse Pyridine-Based Macrocyclic Peptides by a Two-Site Recognition Pathway

Dinh T. Nguyen, Tung T. Le, Andrew J. Rice, Graham A. Hudson, Wilfred A. van der Donk,* and Douglas A. Mitchell*

Cite This: J. Am. Chem. Soc. 2022, 144, 11263−11269

ABSTRACT: Macrocyclic peptides are sought-after molecular scaffolds for drug discovery, and new methods to access diverse libraries are of increasing interest. Here, we report the enzymatic synthesis of pyridine-based macrocyclic peptides (pyritides) from linear precursor peptides. Pyritides are a recently described class of ribosomally synthesized and post-translationally modified peptides (RiPPs) and are related to the long-known thiopeptide natural products. RiPP precursors typically contain an N-terminal leader region that is physically engaged by the biosynthetic proteins that catalyze modification of the C-terminal core region of the precursor peptide. We demonstrate that pyritide-forming enzymes recognize both the leader region and a C-terminal tripeptide motif, with each contributing to site-selective substrate modification. Substitutions in the core region were well-tolerated and facilitated the generation of a wide range of pyritide analogues, with variations in macrocycle sequence and size. A combination of the pyritide biosynthetic pathway with azole-forming enzymes was utilized to generate a thiazole-containing pyritide (historically known as a thiopeptide) with no similarity in sequence and macrocycle size to the naturally encoded pyritides. The broad substrate scope of the pyritide biosynthetic enzymes serves as a future platform for macrocyclic peptide lead discovery and optimization.

INTRODUCTION

Macrocyclic peptide natural products are a privileged class with many members exhibiting potent antibacterial, antifungal, antiviral, anticancer, and immunosuppressive activities. Compared to their linear counterparts, macrocyclic peptides possess desired properties, such as proteolytic stability, increased cell-membrane permeability, and conformational restrictions, resulting in reduced entropy cost upon binding biological targets. These features have increased interest in accessing macrocyclic peptides through combinatorial display, epitope grafting, and cyclization of previously identified linear peptides with activity against biological targets. These efforts are greatly aided by versatile macrocyclization methods that tolerate a wide variety of peptide sequences and that can be executed with large-sized libraries.

Ribosomally synthesized and post-translationally modified peptides (RiPPs) routinely have macrocyclic structures. During RiPP biosynthesis, a gene-encoded precursor peptide undergoes modification by enzymes encoded in a biosynthetic gene cluster (BGC). RiPP precursor peptides are commonly composed of an N-terminal leader region responsible for recruiting biosynthetic proteins and a C-terminal core region that undergoes conversion to the mature RiPP. The physical separation of substrate binding from the site(s) of modification is an attractive feature of RiPP biosynthesis, as it facilitates access to a chemically diverse array of variants. Thus, libraries based on RiPP macrocyclic peptides have been constructed to yield analogues with reprogrammed bioactivity.

Thiopeptides are macrocyclic RiPPs associated with several enticing bioactivities of which potent inhibition of bacterial protein translation is the best studied. Structural analysis of thiopeptides reveals three universal functional groups: azole/azoline heterocycles derived from the ATP-dependent backbone cyclodehydration of Cys, Ser, and Thr residues; dehydroalanine/dehydrobutyrine (Dha/Dhb) and their derivatives resulting from the glutamylation and subsequent elimination of Ser and Thr residues; and a class-defining, six-membered nitrogenous heterocycle resulting from a formal [4 + 2] cycloaddition of two Dha-like residues that coincide with elimination of water and the leader peptide. Accessing thiopeptide derivatives beyond single amino acid substitutions

Received: March 15, 2022
Published: June 17, 2022
has been challenging because of the requirement of multiple azoles in the peptide for downstream Dha formation and \([4 + 2]\) cycloaddition.\(^{17,18,22-26}\) The only thiopxy peptide thus far shown to be amenable to multisite variation is lactazole, for which macrocyclization requires only two azoles and three Dha residues.\(^{27}\)

Recently, we reported a minimalistic, thiopxy peptide-like BGC from \textit{Micromonospora rosaria} that encodes two precursor peptides without Cys residues. The BGC also lacks the genes for azol(in)es formation\(^{28,29}\) and was predicted to produce a pyridine-based macrocyclic peptide (\textit{i.e.}, pyritide, Figure 1).

![Figure 1. Biosynthesis of pyritides. (A) BGC from \textit{Micromonospora rosaria} and sequences of precursor peptides. (B) Reactions catalyzed by MroB and MroC. (C) Reaction catalyzed by the \([4 + 2]\) macrocyclase MroD. (D) Structure of pyritide A1 with the classifying pyridine shown in orange.](image)

Reasoning that the absence of thiazol(in)es would render the pyritide biosynthetic pathway more tolerant of substitutions in the core region, we investigated here the substrate selectivity of pyritide biosynthesis. Other Trp8 (W8G, W8A, W8D, W8N, and W8R) and Ile10 (I10G, I10A, I10N, I10D, and I10W) (Figure 2) for the overall pyritide biosynthesis. Other Trp8 (W8G, W8A, W8D, W8N, and W8R) and Ile10 (I10G, I10A, I10N, I10D, and I10W) variants resulted in inefficient dehydration and macrocyclization (Figures S15 and S22), while didehydrated peptides with nonconservative substitutions at Gly2 (G2A, G2W, and G2R) and Leu9 (L9D, L9R, L9G, L9W, and L9N) were poor substrates for macrocyclization. In contrast, all examined single substitutions of the ring positions (Phe3, Phe4, Gly5, and Arg6) yielded the expected macrocycle.

**Tolerance of the Pyritide Biosynthetic Machinery toward Single-Site Variation.** Having successfully reconstituted the enzymatic biosynthesis of pyritide A1/A2, we next examined whether residues in the core region can be substituted to generate analogues. We first varied each core position of MroA2 with amino acids of different physicochemical properties using \textit{in vitro} transcription and translation,\(^{38}\) generating 52 single-site variants. These variants were subjected to the treatment of MroBCD, and the reaction outcomes were analyzed by MALDI-TOF-MS (Figures S12–S21, Table S5). Only conservative substitutions were well tolerated at Gly2 (G2A, Trp8 (W8Y and W8F), Leu9 (L9I in MroA2), and Ile10 (I10L and I10V) (Figure 2) for the overall pyritide biosynthesis. Other Trp8 (W8G, W8A, W8D, W8N, and W8R) and Ile10 (I10G, I10A, I10N, I10D, and I10W) variants resulted in inefficient dehydration and macrocyclization (Figures S15 and S22), while didehydrated peptides with nonconservative substitutions at Gly2 (G2D, G2L, G2N, G2W, and G2R) and Leu9 (L9D, L9R, L9G, L9W, and L9N) were poor substrates for macrocyclization. In contrast, all examined single substitutions of the ring positions (Phe3, Phe4, Gly5, and Arg6) yielded the expected macrocycle.

**Tolerance of the Biosynthetic Machinery toward Multisite Variation and Ring Expansion and Contraction.** Encouraged by the substrate flexibility in the ring, we next expanded the size and sequence of the macrocycle by inserting 56 different sequences varying in length from three to six residues between the two Ser residues involved in pyridine formation; Gly2 was retained (Figure 3, Table S6). These
substrate variants were treated with MroBCD, and the products were analyzed by MALDI-TOF-MS (Figures S23–S28) and HR-ESI-MS/MS (Figures S29–S37). All 56 variants successfully yielded two Dha residues after treatment with MroBC, illustrating the contrast of this enzyme pair compared to dehydratases from thiopeptide BGCs that often require prior introduction of specific azoles.24,27,39 Reactions including MroD demonstrated that 44 out of 56 didehydrated substrates were macrocyclized (Table S6). We did not observe trends separating substrates and nonsubstrates of MroD in our data set, except the fact that all variants containing Arg or Lys immediately upstream of the C-terminal Dha (equivalent to Arg6 in MroA2) were processed. Hence, positively charged residues at this position are beneficial but not essential. To examine whether an Arg residue at this position would turn nonsubstrates into substrates, Arg was introduced in 11 peptides that previously were poor or nonsubstrates for macrocyclization (Figure S38). Six were cyclized, showing that Arg at this position contributes but is not sufficient to render any sequence a substrate. We then examined whether Thr at this position would be preferred due to its prevalence in natural variants (Table S7). In all investigated substrates, this Thr was bypassed as a site of MroBC-catalyzed dehydration, and six out of ten didehydrated Thr-containing precursors were poor or nonsubstrates for macrocyclization by MroD (Figures S39–S42). Thus, unlike Arg, Thr preceding the second Ser in the core peptide does not facilitate efficient pyritide formation by MroBCD but may be preferable for catalysis by other natural homologues. Further elucidation of the substrate tolerance of MroD will require structural information on core peptide binding. Nonetheless, our data show that whereas some positions are intolerant to variation, much of the precursor peptide tolerates a wide range of substitution, including multiple positively or negatively charged residues.

Pyritides A1 and A2 have 14- and 17-membered rings, respectively. Our substrate engineering efforts show that MroBCD can form 14–23-membered rings with diverse sequences (Table S5). We examined next whether the ring

Figure 3. Panel of variant pyritides. Variations were made in regions in blue. (A) MALDI-TOF-MS of representative multisite pyritide variants. (B) MALDI-TOF-MS of a 68-membered pyritide macrocycle through substitution of Gly by (GlyAsn)9. (C) LC-HR-ESI-MS of a pyritide containing four thiazoles and one thiazoline. Thiazol(in)e residues are bolded in red and abbreviated as Thz. Additional multisite variant data are shown in Tables S5 and S6 and Figures S23–S38 and S44–S49.
size can be further contracted or expanded. Two (Phe4 and Gly5) and three residues (Phe3, Phe4, and Gly5) could be deleted without affecting the dehydration by MroBC, but MroD did not cyclize the dehydrated intermediates to form 8- and 11-membered rings (Figure S43). Thus, the smallest ring size achieved in our data set is a 14-membered ring. Conversely, larger ring sizes were readily accessed including a pyritane macrocycle of 68 atoms via a 17-residue insertion of a Gly−Asn repeat, the longest attempted insertion (Figures S44−S48). Gly−Asn repeats were initially chosen due to their established usage as hydrophilic flexible linkers and were preferred in this work over popular Gly−Ser repeats as they may lead to extra dehydrations and potentially complicate downstream data analysis. We subsequently examined whether MroBCD tolerates large rings with sequences different from Gly−Asn repeats through randomization (Supporting Information). All investigated sequences successfully formed 62-membered macrocycles albeit dehydrated intermediates were also detected (Figure S49).

**Use of MroBCD and TbtEFG for Thiopeptide Formation.** We next investigated whether post-translational modification can be performed on residues inside the pyritane macrocycle. We chose thiazole formation from Cys residues to assess the feasibility of using MroBCD as a platform for thiopeptide engineering. Thus, we inserted the core sequence of the thiomoracin macrocycle (with four C-terminal residues deleted) between the MroA1 leader peptide and the three C-terminal MroA residues (Trp4−Leu10) that were shown above to be important for MroBCD activity. The resulting core sequence shares no similarity with the wild-type sequence (Figure S50). In addition, in the leader peptide of this non-native substrate, we incorporated residues previously identified as critical for the thiazole synthetase TbtEFG (NCBI accession identifier TbtE WP_013130813.1, TbtF WP_206207102.1, and TbtG WP_206207103.1). All Cys residues in the designed substrate peptide were successfully converted to thiazole/thialanine residues after treatment with TbtEFG, and the macrocycle was formed upon reaction with MroBCD (Figures 3C, S50, and S51), opening possibilities to access diverse chemical space of both thiopeptides and pyritides.

**Mechanism of Substrate Recognition.** The broad substrate tolerance, including the ability to significantly expand the size of the macrocycle, combined with the observed importance of the C-terminal tripeptide for catalysis, suggested that MroBCD relies on both the leader region and the C-terminal motif for substrate binding. We tested this hypothesis through analysis of substrate binding to MroB and MroD. Substrate binding to MroC was not investigated as glutamate elimination activity was consistently observed with the substrate variants, suggesting that elimination activity is not limiting. This finding agrees with recent reports showing that MroC homologues recognize glutamylated Ser/Thr rather than a specific peptide sequence. Sequence alignment of pyritane precursor peptides indicated that the first 12 residues in the leader region are not conserved and thus are unlikely to be critical for binding (Table S7). Indeed, a variant of MroA1 in which the first 12 residues were deleted (termed Δ12MroA1) underwent full dehydration and macrocyclization (Figure S52). Fluorescence polarization (FP) measurements indicated that Δ12MroA1 N-terminally labeled with fluoroscope (fluorescein−Δ12MroA1) displayed high affinity toward MBP-MroB and MBP-MroD (KD MroB ≈ 60 nM and KD MroD ≈ 12 nM) (Figure S53). Neither the leader nor the core regions efficiently displaced the labeled precursor peptide (Table 1 and Figures S54 and S55), confirming that MroB and MroD require both for avid binding. We also investigated a panel of MroA1 variants by competition FP assays with fluorescein−Δ12MroA1 (Table 1 and Figures S54 and S55). The binding data with the variants also confirm the importance of the C-terminal tripeptide for MroB (Trp7) and MroD (Trp7, Val8, and Ile9) binding (Figures S56 and S57). To determine if the C-terminal carboxylate is important, we evaluated the binding of MroB to the methyl ester variant of Δ12MroA1, which resulted in approximately eightfold loss in binding affinity (Table 1 and Figure S56). Thus, both binding and activity data point to recognition of the leader peptide and the C-terminal tripeptide.

With the support for two-site recognition by MroB, we investigated how each site contributed to the overall dehydration of MroA1 and MroA2. MroBC assays followed by LC−MS/MS analysis revealed that only Ser1 is predominantly dehydrated in Δ12MroA1 W7G, while only Ser6 is dehydrated in the GlyAla-MroA1 core peptide (Figure 4). These data suggest that the leader peptide is more important for dehydration at Ser1 and the C-terminal tripeptide is more important for dehydration at Ser6. Analogously, the MroA2 variants S7G/W8G and S7G/I10G were completely dehydrated at Ser1, whereas MroA2-S1G/W8G and MroA2-S1G/I10G were inefficiently dehydrated at Ser7 (Figure S60). Dehydration of both MroA2-S1G and MroA2-S7G went to completion, indicating that the two dehydrations are independent of one another.

In summary, we fully reconstituted enzymatic pyritane biosynthesis in vitro, enabling in-depth characterization of the substrate selectivity of the dehydratase MroBCD and the [4 + 2] cycloaddition enzyme MroD. The enzymatic macrocyclization proved to be compatible with in vitro translation, presenting a powerful platform for macrocyclic peptide library construction. Our data support a model in which these enzymes recognize both the leader peptide and the C-terminal tripeptide. The leader peptide is more important for dehydration at the N-
terminal Ser in the core, whereas the C-terminal tripeptide is more important for dehydration at Ser6/7. By keeping the leader peptide and C-terminal residues invariant, we generated pyritide analogues with diverse ring sequences and sizes (14–68 membered). These data will facilitate future efforts in the bioengineering of macrocyclic peptides with desirable properties.

ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/jacs.2c02824.

Experimental procedures and supporting figures and tables (PDF)
Primer sequences (XLSX)
MS data (XLSX)

AUTHOR INFORMATION

Corresponding Authors

Wilfred A. van der Donk – Department of Chemistry, Carl R. Woese Institute for Genomic Biology, and Howard Hughes Medical Institute, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0002-5467-7071; Email: vddonk@illinois.edu

Douglas A. Mitchell – Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0002-9564-0953; Phone: 1-217-333-1345; Email: douglasm@illinois.edu

Authors

Dinh T. Nguyen – Department of Chemistry, Carl R. Woese Institute for Genomic Biology, and Howard Hughes Medical Institute, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0002-2101-6808

Tung T. Le – Department of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0003-0278-0955

Andrew J. Rice – Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0001-8794-3826

Graham A. Hudson – Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0002-3715-4279

Complete contact information is available at: https://pubs.acs.org/10.1021/jacs.2c02824

Funding

This work was supported by the Howard Hughes Medical Institute, the National Institutes of Health (GM097142 to D.A.M.), the Chemistry–Biology Interface Research Training Program, GM070421 (to A.J.R.), and the Seemon Pines Fellowship from the Department of Chemistry at the University of Illinois (to G.A.H.). This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program under grant no. DGE 21-46756 (to A.J.R.).

Notes

The authors declare the following competing financial interest(s): The technology disclosed within this manuscript has been submitted as a provisional patent.

ACKNOWLEDGMENTS

We thank Y. Yu, S. Ramesh, and T. Precord for their assistance with HR-MS/MS experiments. This study is subject to the Open Access to Publications policy of the Howard Hughes Medical Institute (HHMI). HHMI laboratory heads have previously granted a nonexclusive CC BY 4.0 license to the public and a sublicensable license to HHMI in their research articles. Pursuant to those licenses, the author-accepted manuscript of this article can be made freely available under a CC BY 4.0 license immediately upon publication.

REFERENCES

(1) Bockus, A. T.; McEwen, C. M.; Lokey, R. S. Form and function in cyclic peptide natural products: a pharmacokinetic perspective. Curr. Top. Med. Chem. 2013, 13, 821.

(2) Choi, J.-S.; Joo, S. H. Recent trends in cyclic peptides as therapeutic agents and biochemical tools. Biomat. Ther. 2020, 28, 18.
(3) Nielsen, D. S.; Shepherd, N. E.; Xu, W.; Lucke, A. J.; Stoermer, M. J.; Fairlie, D. P. Orally absorbed cyclic peptides. Chem. Rev. 2017, 117, 8094.

(4) Vinogradov, A. A.; Yin, Y.; Suga, H. Macrocyclic peptides as drug candidates: recent progress and remaining challenges. J. Am. Chem. Soc. 2019, 141, 4167.

(5) Sohrabi, C.; Foster, A.; Tavassoli, A. Methods for generating and screening libraries of genetically encoded cyclic peptides in drug discovery. Nat. Rev. Chem. 2020, 4, 90.

(6) Wang, C. K.; Gruber, C. W.; Cemazar, M.; Siatskas, C.; Tagore, P.; Payne, N.; Sun, G.; Wang, S.; Bernard, C. C.; Craik, D. J. Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis. ACS Chem. Biol. 2014, 9, 156.

(7) Veber, D. F.; Freidinger, R. M.; Perlow, D. S.; Paleveda, W. J., Jr.; Holly, F. W.; Strachan, R. G.; Nutt, R. F.; Arison, B. H.; Homnick, C.; Randall, W. C.; Glitzer, M. S.; Saperstein, R.; Hirschmann, R. A potent cyclic hexapeptide analogue of somatostatin. Nature 1981, 292, 55.

(8) Chow, H. Y.; Zhang, Y.; Matheson, E.; Li, X. Ligation technologies for the synthesis of cyclic peptides. Chem. Rev. 2019, 119, 9971.

(9) Reguera, L.; Rivera, D. G. Multicomponent reaction toolbox for peptide macrocyclization and stapling. Chem. Rev. 2019, 119, 9836.

(10) Liu, D.; Rubin, G. M.; Dhakal, D.; Chen, M.; Ding, Y. Biocatalytic synthesis of peptidic natural products and related analogues. Science 2021, 24, 102512.

(11) Montalbán-López, M.; Scott, T. A.; Ramesh, S.; Rahman, I. R.; van Heel, A. J.; Viel, J. H.; Bandarian, V.; Dittmann, E.; Genilloud, O.; Goto, Y.; Grande Burgos, M. J.; Hill, C.; Kim, S.; Koechnke, J.; Latham, A. J.; Link, A. J.; Martinez, B.; Nair, S. K.; Nicolet, Y.; Rebuffat, S.; Sahl, H.-G.; Sareen, D.; Schmidt, E. W.; Schmitt, L.; Severinov, K.; Süssmuth, R. D.; Truman, A. W.; Wang, H.; Weng, J.-K.; van Wezel, G. P.; Zhang, Q.; Zhong, J.; Pielt, J.; Mitchell, D. A.; Kuipers, O. P.; van der Donk, W. A. New developments in RiPP discovery, enzymology and engineering. Nat. Prod. Rep. 2021, 38, 130.

(12) Schmitt, S.; Montalbán-López, M.; Peterhoff, D.; Deng, J.; Wagner, R.; Held, M.; Kuipers, O. P.; Panke, S. Analysis of modular bioengineered antimicrobial lantipeptides at nanoliter scale. Nat. Chem. Biol. 2019, 15, 437.

(13) Yang, X.; Lennard, K. R.; He, C.; Walker, M. C.; Ball, A. T.; Doigneaux, C.; Tavassoli, A.; van der Donk, W. A. A lanthipeptide library used to identify a protein-protein interaction inhibitor. Nat. Chem. Biol. 2018, 14, 375.

(14) Hetrick, K. J.; Walker, M. C.; van der Donk, W. A. Development and application of yeast and phage display of diverse lantipeptides. ACS Cent. Sci. 2018, 4, 458.

(15) Urban, J. H.; Moosmeier, M. A.; Aumüller, T.; Thein, M.; Bosma, T.; Rink, R.; Groth, K.; Zulley, M.; Siegers, K.; Tissot, K.; Moll, G. N.; Prassler, J.; Lanthipeptide structure, conformation, and activity of heterocycle substitution mutants. J. Am. Chem. Soc. 2010, 132, 7519.

(16) Reyna-González, E.; Schmid, B.; Petras, D.; Süssmuth, R. D.; Dittmann, E. Leader peptide-free in vitro reconstitution of microsomal pyridine synthase recognition sequences allows a modular solid-phase route to thiopeptide thiomuracin. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 3615.

(17) Schmitt, S.; Montalbán-López, M.; Peterhoff, D.; Deng, J.; Wagner, R.; Held, M.; Kuipers, O. P.; Panke, S. Analysis of modular bioengineered antimicrobial lantipeptides at nanoliter scale. Nat. Chem. Biol. 2019, 15, 437.

(18) Montalbán-López, M.; Scott, T. A.; Ramesh, S.; Rahman, I. R.; van Heel, A. J.; Viel, J. H.; Bandarian, V.; Dittmann, E.; Genilloud, O.; Goto, Y.; Grande Burgos, M. J.; Hill, C.; Kim, S.; Koechnke, J.; Latham, A. J.; Link, A. J.; Martinez, B.; Nair, S. K.; Nicolet, Y.; Rebuffat, S.; Sahl, H.-G.; Sareen, D.; Schmidt, E. W.; Schmitt, L.; Severinov, K.; Süssmuth, R. D.; Truman, A. W.; Wang, H.; Weng, J.-K.; van Wezel, G. P.; Zhang, Q.; Zhong, J.; Pielt, J.; Mitchell, D. A.; Kuipers, O. P.; van der Donk, W. A. New developments in RiPP discovery, enzymology and engineering. Nat. Prod. Rep. 2021, 38, 130.

(19) Schmitt, S.; Montalbán-López, M.; Peterhoff, D.; Deng, J.; Wagner, R.; Held, M.; Kuipers, O. P.; Panke, S. Analysis of modular bioengineered antimicrobial lantipeptides at nanoliter scale. Nat. Chem. Biol. 2019, 15, 437.

(20) Yang, X.; Lennard, K. R.; He, C.; Walker, M. C.; Ball, A. T.; Doigneaux, C.; Tavassoli, A.; van der Donk, W. A. A lanthipeptide library used to identify a protein-protein interaction inhibitor. Nat. Chem. Biol. 2018, 14, 375.

(21) Veber, D. F.; Freidinger, R. M.; Perlow, D. S.; Paleveda, W. J., Jr.; Holly, F. W.; Strachan, R. G.; Nutt, R. F.; Arison, B. H.; Homnick, C.; Randall, W. C.; Glitzer, M. S.; Saperstein, R.; Hirschmann, R. A potent cyclic hexapeptide analogue of somatostatin. Nature 1981, 292, 55.

(22) Chow, H. Y.; Zhang, Y.; Matheson, E.; Li, X. Ligation technologies for the synthesis of cyclic peptides. Chem. Rev. 2019, 119, 9971.

(23) Liu, D.; Rubin, G. M.; Dhakal, D.; Chen, M.; Ding, Y. Biocatalytic synthesis of peptidic natural products and related analogues. Science 2021, 24, 102512.

(24) Montalbán-López, M.; Scott, T. A.; Ramesh, S.; Rahman, I. R.; van Heel, A. J.; Viel, J. H.; Bandarian, V.; Dittmann, E.; Genilloud, O.; Goto, Y.; Grande Burgos, M. J.; Hill, C.; Kim, S.; Koechnke, J.; Latham, A. J.; Link, A. J.; Martinez, B.; Nair, S. K.; Nicolet, Y.; Rebuffat, S.; Sahl, H.-G.; Sareen, D.; Schmidt, E. W.; Schmitt, L.; Severinov, K.; Süssmuth, R. D.; Truman, A. W.; Wang, H.; Weng, J.-K.; van Wezel, G. P.; Zhang, Q.; Zhong, J.; Pielt, J.; Mitchell, D. A.; Kuipers, O. P.; van der Donk, W. A. New developments in RiPP discovery, enzymology and engineering. Nat. Prod. Rep. 2021, 38, 130.

(25) Schmitt, S.; Montalbán-López, M.; Peterhoff, D.; Deng, J.; Wagner, R.; Held, M.; Kuipers, O. P.; Panke, S. Analysis of modular bioengineered antimicrobial lantipeptides at nanoliter scale. Nat. Chem. Biol. 2019, 15, 437.

(26) Veber, D. F.; Freidinger, R. M.; Perlow, D. S.; Paleveda, W. J., Jr.; Holly, F. W.; Strachan, R. G.; Nutt, R. F.; Arison, B. H.; Homnick, C.; Randall, W. C.; Glitzer, M. S.; Saperstein, R.; Hirschmann, R. A potent cyclic hexapeptide analogue of somatostatin. Nature 1981, 292, 55.
(40) Zhao, R.; Goldstein, S. A. N. Tethered peptide toxins for ion channels. *Methods Enzymol.* 2021, 654, 203.

(41) Gräwe, A.; Ranglack, J.; Weyrich, A.; Stein, V. iFLinkC: an iterative functional linker cloning strategy for the combinatorial assembly and recombination of linker peptides with functional domains. *Nucleic Acids Res.* 2020, 48, No. e24.

(42) Mack, M.; Riethmüller, G.; Kufer, P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. *Proc. Natl. Acad. Sci. U.S.A.* 1995, 92, 7021.

(43) Lee, H.; Shu, L.; De Pascalis, R.; Giuliano, M.; Zhu, M.; Padlan, E. A.; Hand, P. H.; Schlom, J.; Hong, H. J.; Kashmiri, S. V. Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. *Mol. Immunol.* 1999, 36, 61.

(44) Oman, T. J.; Knerr, P. J.; Bindman, N. A.; Velásquez, J. E.; van der Donk, W. A. An engineered lantibiotic synthetase that does not require a leader peptide on its substrate. *J. Am. Chem. Soc.* 2012, 134, 6952.

(45) Vinogradov, A. A.; Nagano, M.; Goto, Y.; Suga, H. Site-specific nonenzymatic peptide S/O-glutamylation reveals the extent of substrate promiscuity in glutamate elimination domains. *J. Am. Chem. Soc.* 2021, 143, 13358.

(46) Huo, L.; Zhao, X.; Acedo, J. Z.; Estrada, P.; Nair, S. K.; van der Donk, W. A. Characterization of a dehydratase and methyltransferase in the biosynthesis of ribosomally synthesized and post-translationally modified peptides in Lachnospiraceae. *ChemBioChem* 2020, 21, 190.